Characteristics of included subjects in the sepsis and CRS groups
| . | CRS subjects (N = 16) . | Sepsis subjects (N = 80) . |
|---|---|---|
| Age*, median (IQR), y | 14.5 (9.6-17.1) | 6.7 (2.9-13.5) |
| Sex, n (%) | ||
| Female | 7 (44) | 37 (46) |
| Male | 9 (56) | 43 (54) |
| Race, n (%) | ||
| White | 14 (88) | 39 (49) |
| Black/African American | 1 (6) | 20 (25) |
| Asian | 1 (6) | 3 (4) |
| Indian | 0 | 2 (3) |
| Other | 0 | 15 (19) |
| Unknown | 0 | 1 (1) |
| Any vasoactive agent, n (%) | 12 (75) | 63 (79) |
| Any invasive mechanical ventilation, n (%) | 2 (13) | 53 (66) |
| Any corticosteroids (sepsis) or tocilizumab or corticosteroids (CRS), n (%) | 12 (75) | 39 (49) |
| WBC count, median (IQR), ×109/L | 0.25 (0.1, 0.5) | 9.60 (6.1, 16.3) (n = 72) |
| ALC, median (IQR), ×106/L | 37.5 (0, 157) | 1262 (711, 2588) (n = 72) |
| Highest lactate, median (IQR), mmol/L | 2.1 (1.4-3.4) | 2.30 (1.5-3.7) |
| Hematologic dysfunction,† n (%) | 5 (31) | 21 (26) |
| Hepatic dysfunction, n (%) | 0 (0) | 16 (20) |
| Acute kidney injury, n (%) | 3 (19) | 7 (9) |
| Creatinine, median (IQR), mg/dL | 0.7 (0.5-1.1) | 0.4 (0.3-0.65) |
| Malignancy, n (%) | 16 (100) | 9 (12) (n = 12) |
| Infection, n (%) | ||
| Bacterial | 2‡ (100) | 26 (32) |
| Bacterial‡ other§ | 10 (12) | |
| Viral | 19 (24) | |
| None identified | 25 (31) | |
| UPENN CRS (1st) severity score/grade, n (%) | ||
| 3 | 5 (31) | |
| 4 | 11 (69) | |
| 5 | 0 (0) | |
| ASTCT CRS severity score/grade: n (%) | ||
| 2 | 2 (12) | |
| 3 | 3 (19) | |
| 4 | 11 (69) |
| . | CRS subjects (N = 16) . | Sepsis subjects (N = 80) . |
|---|---|---|
| Age*, median (IQR), y | 14.5 (9.6-17.1) | 6.7 (2.9-13.5) |
| Sex, n (%) | ||
| Female | 7 (44) | 37 (46) |
| Male | 9 (56) | 43 (54) |
| Race, n (%) | ||
| White | 14 (88) | 39 (49) |
| Black/African American | 1 (6) | 20 (25) |
| Asian | 1 (6) | 3 (4) |
| Indian | 0 | 2 (3) |
| Other | 0 | 15 (19) |
| Unknown | 0 | 1 (1) |
| Any vasoactive agent, n (%) | 12 (75) | 63 (79) |
| Any invasive mechanical ventilation, n (%) | 2 (13) | 53 (66) |
| Any corticosteroids (sepsis) or tocilizumab or corticosteroids (CRS), n (%) | 12 (75) | 39 (49) |
| WBC count, median (IQR), ×109/L | 0.25 (0.1, 0.5) | 9.60 (6.1, 16.3) (n = 72) |
| ALC, median (IQR), ×106/L | 37.5 (0, 157) | 1262 (711, 2588) (n = 72) |
| Highest lactate, median (IQR), mmol/L | 2.1 (1.4-3.4) | 2.30 (1.5-3.7) |
| Hematologic dysfunction,† n (%) | 5 (31) | 21 (26) |
| Hepatic dysfunction, n (%) | 0 (0) | 16 (20) |
| Acute kidney injury, n (%) | 3 (19) | 7 (9) |
| Creatinine, median (IQR), mg/dL | 0.7 (0.5-1.1) | 0.4 (0.3-0.65) |
| Malignancy, n (%) | 16 (100) | 9 (12) (n = 12) |
| Infection, n (%) | ||
| Bacterial | 2‡ (100) | 26 (32) |
| Bacterial‡ other§ | 10 (12) | |
| Viral | 19 (24) | |
| None identified | 25 (31) | |
| UPENN CRS (1st) severity score/grade, n (%) | ||
| 3 | 5 (31) | |
| 4 | 11 (69) | |
| 5 | 0 (0) | |
| ASTCT CRS severity score/grade: n (%) | ||
| 2 | 2 (12) | |
| 3 | 3 (19) | |
| 4 | 11 (69) |